GUANFACINE HYDROCHLORIDE (guanfacine) by Rubicon Biotechnology is clinical pharmacology guanfacine tablets, usp are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. Approved for the management of hypertension, hypertension. First approved in 2023.
Drug data last refreshed 1w ago
CLINICAL PHARMACOLOGY Guanfacine Tablets, USP are an orally active antihypertensive agent whose principal mechanism of action appears to be stimulation of central α 2 -adrenergic receptors. By stimulating these receptors, guanfacine reduces sympathetic nerve impulses from the vasomotor center to…
Worked on GUANFACINE HYDROCHLORIDE at Rubicon Biotechnology? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS)
Access to Extended Release Guanfacine HCl for Subjects Who Participated in Studies SPD503-315 or SPD503-316 in Europe
Guanfacine for the Treatment of Hyperactivity in Pervasive Developmental Disorder
Dose-optimization in Adolescents Aged 13-17 Diagnosed With Attention-deficit/Hyperactivity Disorder (ADHD) Using Extended-release Guanfacine HCl
Efficacy and Safety of Extended-release Guanfacine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD)